AGEN 250117 3.00C (AGEN250117C3000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

AGEN250117C3000

Watchlist

0.25
0.000.00%

15min DelayClose Dec 30 10:39 ET

0.26High0.25Low

Intraday

5D
Daily

News

Express News | Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
BenzingaDec 18 07:35 ET
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating
Moomoo NewsDec 5 12:35 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral
BenzingaDec 5 11:12 ET
Agenus Announces Strategic Realignment
TipRanksDec 5 07:35 ET
Express News | Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
ReutersDec 5 07:30 ET
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7
Moomoo NewsNov 27 12:31 ET · Ratings

Comments

Trytosaveabit

Dec 18 06:40

Update

$Agenus (AGEN.US)$ Benzinga· 3 mins ago
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Jaguar8

Dec 5 06:32

NEWS

$Agenus (AGEN.US)$
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
1 minute ago, 4:30 AM PST
Via BusinessWire
Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. T...

Jaguar8

Nov 27 07:15

NEWS

$Agenus (AGEN.US)$
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus (NASDAQ: AGEN) has secured a $22 million mortgage backed by its Berkeley and Vacaville properties, providing $20 million in net proceeds.
The two-year mortgage includes interest payable 50% in cash and 50% in common stock, at rates of 12% for Year 1 and 13% for Year 2.
The company announced a Strategic Operational Realignment Plan focusing on botensilimab/balstilimab(BOT/BAL) in MSS...

Martin J

Nov 22 10:50

🚀🚀🚀

Share Your Profit/Loss

Jaguar8

Nov 7 09:02

NEWS

$Agenus (AGEN.US)$
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstr...